Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Advances in Novel Drug Discovery, Synthesis, and Evaluation
share announcement

Advances in Novel Drug Discovery, Synthesis, and Evaluation

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 616

Special Issue Editor

Dr. Khaled M. Elokely

E-Mail
Guest Editor
Division of Pharmaceutical Sciences, School of Pharmacy, College of Health Sciences, University of Wyoming, Laramie, WY 82071, USA
Interests: drug discovery and development; design and synthesis of novel therapeutic agents; bioactive compounds

Special Issue Information

Dear Colleagues,

The Special Issue titled "Advances in Novel Drug Discovery, Synthesis, and Evaluation" focuses on the latest developments in drug development, highlighting new strategies and methods for synthesizing and evaluating therapeutic agents for a wide range of diseases. As we confront diverse health challenges, including infectious diseases, cancer, and neurodegenerative disorders, the demand for innovative solutions is more critical than ever.

This Special Issue invites contributions that explore practical techniques in medicinal chemistry, such as structure-based drug design, and advancements in synthetic methodologies that enhance the efficiency of drug development. Additionally, contributions on computational modeling, artificial intelligence, and high-throughput screening are encouraged, as these tools play essential roles in streamlining the drug discovery process and optimizing candidate selection.

We welcome original research articles, comprehensive reviews, and insightful case studies that discuss the current challenges in the field while offering promising advancements and future directions.

Dr. Khaled M. Elokely
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug synthesis
  • novel therapies
  • disease targets
  • medicinal chemistry
  • computational methods
  • screening techniques
  • pharmaceutical development
  • target identification

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

25 pages, 5557 KiB  
Article
Evaluation of the Effects of the Quaternary Ammonium Silane K21 on Zebrafish Viability, Toxicity, Growth, and Development
by Surendra K. Rajpurohit, Devan Anmol S. Manhiani, Ashwin Ajith, Pragya Rajpurohit, Simran Hotwani, Sai Nasanally, Arsha Sreekumar, Keshu Bhat, Aiden Van Derhei, Rohan Pasi, Arishia Mishra, Kirk Kimmerling and Clifton M. Carey
Biomedicines 2025, 13(6), 1267; https://doi.org/10.3390/biomedicines13061267 - 22 May 2025
Viewed by 376
Abstract
Background: The FDA-cleared antimicrobial quaternary ammonium silane K21 is recognized for its antimicrobial properties. This study explored potential applications of the K21 molecule in human health protection, disease prevention, and treatment using the zebrafish model. Method: A multi-dimensional approach was utilized [...] Read more.
Background: The FDA-cleared antimicrobial quaternary ammonium silane K21 is recognized for its antimicrobial properties. This study explored potential applications of the K21 molecule in human health protection, disease prevention, and treatment using the zebrafish model. Method: A multi-dimensional approach was utilized to assess the toxicity, tolerance, and optimal dosage of K21 through serial dilutions at various concentrations. Acute and chronic exposure studies were performed at different developmental stages (embryonic, larval, juvenile, and adult) to evaluate its efficacy and toxicity in wild-type (WT), Casper (transparent skin mutant), and transgenic zebrafish lines. Results: Significant weight gain was observed in the F1 generation following K21 treatment, a trend that continued into the F2 and F3 generations. The effects of K21 on lipopolysaccharide-induced inflammation were also examined in Casper NFkB:GFP transgenic lines. Treatment with K21 reduced inflammation, indicating anti-inflammatory properties. Improved hatching rates, accelerated larval development, an increased adult mass, and modest reductions in embryonic motility (less than 20%) suggested positive developmental influences. Single-cell RNA sequencing further validated the biological impacts of K21, revealing the potential activation of a novel pathway that accelerates zebrafish growth. Summary and Conclusions: These findings position K21 as a promising candidate for biomedical applications and aquaculture, warranting further investigation into its underlying molecular mechanisms. Our additional study on the effect of K21 on the artemia (brine shrimp) hatching process provide strong evidence of better hatching ratio of 90% for brine shrimp in the group with K21 drug treatment as compared to 70% in the group without the K21 drug at 24 h of treatment; the K21 drug helps the early hatching process, as observed the 90% hatching rate in 20 h K21 treatment group hatching while in the group without K21, only 40% of brine shrimps hatched. Full article
(This article belongs to the Special Issue Advances in Novel Drug Discovery, Synthesis, and Evaluation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop